197960-66-0

Basic information

• Product Name: Benzenesulfonic acid, 2-(methylsulfonyl)-, 3-hydroxy-5-methylphenyl ester
• CAS NO: 197960-66-0
• Molecular Formula: C14H14O6S2
• Molecular Weight: 342.394
• Mol File: 197960-66-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzenesulfonic acid, 2-(methylsulfonyl)-, 3-hydroxy-5-methylphenyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenesulfonic acid, 2-(methylsulfonyl)-, 3-hydroxy-5-methylphenyl ester(197960-66-0)
• EPA Substance Registry System: Benzenesulfonic acid, 2-(methylsulfonyl)-, 3-hydroxy-5-methylphenyl ester(197960-66-0)

Safety Data

• Hazardous Substances Data: 197960-66-0(Hazardous Substances Data)

Usage

General Description

Benzenesulfonic acid, 2-(methylsulfonyl)-, 3-hydroxy-5-methylphenyl ester, also known as Diampromide, is a chemical compound that is commonly used as a medication to relieve pain. It belongs to the class of compounds known as phenylsulfonates and is often used as an analgesic and antipyretic agent. It is commonly found in over-the-counter pain relief medications and works by blocking the production of certain natural substances that cause pain and inflammation in the body. It is important to use this medication as directed by a healthcare professional to avoid any potential side effects.

Upstream product

• 89265-35-0 2-Methanesulfonyl-benzenesulfonyl chloride 
• 6153-39-5 5-Methylresorcinol monohydrate 
• 504-15-4 orcinol 

Downstream Products

• 197960-67-1 3-[5-methyl-3-[2-(methylsulfonyl)phenylsulfonyloxy]phenoxy]propanol 
• 208643-39-4 2-[5-methyl-3-(2-(methylsulfonyl)phenylsulfonyloxy)phenoxy]ethanol 
• 208643-41-8 2-hydroxy-3-[5-methyl-3-(2-methylsulfonyl)phenylsulfonyloxyphenoxy]propanol 
• 208642-96-0 2-methanesulfonyl-benzenesulfonic acid 3-(1-hydroxymethyl-cyclopropylmethoxy)-5-methyl-phenyl ester 
• 197960-68-2 3-[5-methyl-3-[2-(methylsulfonyl)phenylsulfonyloxy]phenoxy]-propionaldehyde 
• 208644-21-7 C₂₈H₃₉N₃O₁₁S₂ 

Relevant articles and documents

AMIDINOHYDRAZONES AS PROTEASE INHIBITORS

Amidino and benzamidino compounds, including compounds of the formula: I wherein R1-R4, R6-R9, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I.

Aminoguanidines and alkoxyguanidines as protease inhibitors

Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula: wherein X is O or NR9and R114 R4, R6-R9, R11, R12, Ra, Rb, Rc, Y, Z, n and mare set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

AMIDINOHYDRAZONES AS PROTEASE INHIBITORS

Amidino and benzamidino compounds, including compounds of the formula: STR1 wherein R 1-R 4, R 6-R 9, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I.